Related Experiment Video
Updated: Apr 24, 2026

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
Published on: February 10, 2022
Robust immunoreaction induced by a subunit vaccine of PEDV spike protein based on GEM surface-display system
Xuwen Qiao1, Luping Du2, Zhu Qin1
1Institute of Veterinary Immunology & Engineering, Jiangsu Academy of Agricultural Sciences, Nanjing, Jiangsu 210014, China; Guo Tai (Taizhou) Center of Technology Innovation for Veterinary Biologicals, Taizhou 225300, China.
Abstract:
The global porcine epidemic diarrhea (PED) pandemic underscores the urgent need for safe, effective, and readily deployable subunit vaccines against porcine epidemic diarrhea virus (PEDV). In this study, we developed a subunit vaccine by displaying the PEDV spike (S) protein on Gram-positive enhancer matrix (GEM) particles via a protein anchor (PA), resulting in stable particulate antigen complexes designated GEM-S. The immunogenicity of GEM-S was evaluated in mice. Immune responses in lymph nodes (LNs), spleen, and serum were assessed using reverse transcription-quantitative polymerase chain reaction (RT-qPCR), flow cytometry, enzyme-linked immunosorbent assay (ELISA), and virus neutralization assays. Compared to soluble S protein, both GEM-S and the oil-adjuvanted control 206-S significantly upregulated cytokine/chemokine expression, increased antigen-presenting cell (APC) numbers in LNs, enhanced co-stimulatory molecule expression on dendritic cells (DCs), and elevated systemic antibody titers. Notably, GEM-S induced a higher IgG2a/IgG1 ratio, stronger intestinal mucosal IgA production, and a more sustained antibody response than 206-S, despite generating lower total IgG levels. These findings indicate that the particulate GEM-S formulation can effectively elicit robust PEDV-specific humoral and mucosal immune responses in mice, supporting its further investigation as a promising subunit vaccine candidate against PEDV.
More Related Videos
08:07A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
Published on: July 25, 2022
08:07Author Spotlight: Advancing Antiviral Strategies Through Novel Immunocapture and Mass Spectrometry Techniques
Published on: January 12, 2024